BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 11355911)

  • 1. The pathology of epithelial pre-malignancy of the gastrointestinal tract.
    Guindi M; Riddell RH
    Best Pract Res Clin Gastroenterol; 2001 Apr; 15(2):191-210. PubMed ID: 11355911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new Vienna classification of epithelial neoplasia of the gastrointestinal tract: advantages and disadvantages.
    Stolte M
    Virchows Arch; 2003 Feb; 442(2):99-106. PubMed ID: 12596058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysplasia can be a pain in the gut.
    McKenna BJ; Appelman HD
    Pathology; 2002 Dec; 34(6):518-28. PubMed ID: 12555989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International comparability of the pathological diagnosis for early cancer of the digestive tract: Munich meeting.
    Schlemper RJ; Borchard F; Dixon MF; Koike M; Mueller J; Stolte M; Watanabe H
    J Gastroenterol; 2000; 35 Suppl 12():102-10. PubMed ID: 10779228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Well-differentiated adenocarcinoma or dysplasia of the gastric epithelium: rationale for a new classification system.
    Schlemper RJ; Kato Y; Stolte M
    Verh Dtsch Ges Pathol; 1999; 83():62-70. PubMed ID: 10714196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological assessment of oesophageal columnar mucosa.
    Flejou JF
    Best Pract Res Clin Gastroenterol; 2008; 22(4):671-86. PubMed ID: 18656824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
    Armstrong D
    Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoplastic precursor lesions in Barrett's esophagus.
    Hornick JL; Odze RD
    Gastroenterol Clin North Am; 2007 Dec; 36(4):775-96, v. PubMed ID: 17996790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
    Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
    BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies.
    Downs-Kelly E; Mendelin JE; Bennett AE; Castilla E; Henricks WH; Schoenfield L; Skacel M; Yerian L; Rice TW; Rybicki LA; Bronner MP; Goldblum JR
    Am J Gastroenterol; 2008 Sep; 103(9):2333-40; quiz 2341. PubMed ID: 18671819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Senescence-associated' beta-galactosidase activity in the upper gastrointestinal tract.
    Going JJ; Stuart RC; Downie M; Fletcher-Monaghan AJ; Keith WN
    J Pathol; 2002 Apr; 196(4):394-400. PubMed ID: 11920734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barrett's oesophagus--a pathologist's view.
    Fléjou JF; Svrcek M
    Histopathology; 2007 Jan; 50(1):3-14. PubMed ID: 17204017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of Barrett's oesophagus. A general survey.
    Petrakis IE; Sciacca V; Iascone C
    Acta Chir Belg; 2001; 101(2):53-8. PubMed ID: 11396051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of malignant potential between serrated adenomas and traditional adenomas.
    Song SY; Kim YH; Yu MK; Kim JH; Lee JM; Son HJ; Rhee PL; Kim JJ; Paik SW; Rhee JC
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1786-90. PubMed ID: 17914951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?
    Rubin DT; Rothe JA; Hetzel JT; Cohen RD; Hanauer SB
    Gastrointest Endosc; 2007 Jun; 65(7):998-1004. PubMed ID: 17451704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
    Quera R; O'Sullivan K; Quigley EM
    Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
    Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
    Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.